IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]
covid, candidate, nanoparticle, vaccine, under, development, icosavax, currently, undergoing, phase, clinical, trial, australia, originally, developed, institute, protein, design, university, washington, school, medicine, both, based, university, washington, 4. IVX 411 is a COVID 19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I II clinical trial in Australia 1 It was originally developed at the Institute of Protein Design IPD and the University of Washington School of Medicine both based at the University of Washington 2 3 4 IX 411Vaccine descriptionTargetSARS CoV 2Vaccine typeVirus like particlesClinical dataRoutes ofadministrationIntramuscularReferences edit ANZCTR Registration anzctr org au Retrieved 18 August 2021 Icosavax Initiates Phase 1 2 Trial of COVID 19 VLP Vaccine Candidate Icosavax Inc investors icosavax com Retrieved 18 August 2021 Two nanoparticle vaccines enter clinical trials Institute for Protein Design 2 June 2021 Retrieved 18 August 2021 Arunachalam PS Walls AC Golden N Atyeo C Fischinger S Li C et al June 2021 Adjuvanting a subunit COVID 19 vaccine to induce protective immunity Nature 594 7862 253 258 Bibcode 2021Natur 594 253A doi 10 1038 s41586 021 03530 2 PMID 33873199 Portals nbsp Medicine nbsp Viruses nbsp COVID 19 nbsp This article about COVID 19 vaccines is a stub You can help Wikipedia by expanding it vte nbsp This article about vaccines or vaccination is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title IVX 411 amp oldid 1180154135, wikipedia, wiki, book, books, library,
